scout
Opinion|Videos|December 13, 2023

Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.

Episodes in this series

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME